Literature DB >> 4558895

The comparative value of amantadine and levodopa.

V Dallos, K Heathfield, P Stone, F Allen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4558895      PMCID: PMC2495225     

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  9 in total

1.  Amantadine dosage in treatment of Parkinson's disease.

Authors:  J D Parkes; K J Zilkha; P Marsden; R C Baxter; R P Knill-Jones
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

2.  Trimethylaminuria: the fish-odour syndrome.

Authors:  J A Humbert; K B Hammond; W E Hathaway
Journal:  Lancet       Date:  1970-10-10       Impact factor: 79.321

3.  Amantadine in parkinsonism.

Authors:  K R Hunter; G M Stern; D R Laurence; P Armitage
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

4.  Amantadine in Parkinsonism. An extended prospective trial.

Authors:  N S Rao; J Pearce
Journal:  Practitioner       Date:  1971-02

5.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

6.  Incidence of side effects from levodopa during the introduction of treatment.

Authors:  R B Godwin-Austen; C C Frears; S Bergmann
Journal:  Br Med J       Date:  1971-01-30

7.  Amantadine versus L-2 dopa and amatadine plus L-dopa.

Authors:  C Fieschi; M Nardini; M Casacchia; M E Tedone; M Reitano; E Robotti
Journal:  Lancet       Date:  1970-07-18       Impact factor: 79.321

8.  Use of amantadine in Parkinson's disease. Results of a double-blind trial.

Authors:  V Dallos; K Heathfield; P Stone; F A Allen
Journal:  Br Med J       Date:  1970-10-03

9.  L-dopa in Parkinsonism and the influence of previous thalamotomy.

Authors:  R C Hughes; J G Polgar; D Weightman; J N Walton
Journal:  Br Med J       Date:  1971-01-02
  9 in total
  4 in total

Review 1.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.